Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals conducts animal testing as a core component of its drug development and regulatory compliance process. The company’s preclinical studies for its hematology-focused pipeline, including products like fostamatinib (TAVALISSE®) and olutasidenib (REZLIDHIA®), explicitly involve animal studies to evaluate efficacy and safety. Its SEC filings and FDA submissions document that these studies are performed in compliance with Good Laboratory Practice (GLP) regulations, a standard requirement for new drug applications.

Specific FDA review documents for REZLIDHIA note that animal studies identified embryofetal lethality and decreased fetal weights at high doses. As a commercial-stage biotechnology company, Rigel’s research model is built on the use of animal data to demonstrate safety and efficacy to regulators, a practice currently mandated by U.S. federal law for new treatment approvals. The company has not publicly committed to adopting or funding alternative non-animal testing methods as part of its development strategy.